Your search for rivaroxaban returned 152 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for rivaroxaban returned 152 results

Sort Results:

Relevant Recent
Drug Monograph Updates

August 2016 Recap of Drug Updates

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of August. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
Drugs in the Pipeline

FDA Wants More Data for Anticoagulant Antidote AndexXa

The FDA has issued a Complete Response Letter (CRL) to the Biologics License Application (BLA) of AndexXa (andexanet alfa; Portola) as a reversal agent for life-threatening or uncontrolled bleeding due to Factor Xa inhibitors.
News

Bleeding Rates High After Dual Antiplatelet Therapy, Post-PCI

For patients with atrial fibrillation at moderate to high risk of stroke, dual antiplatelet therapy (DAPT) use is variable among those undergoing percutaneous coronary intervention (PCI), according to a study published in JACC: Cardiovascular Interventions.
News

Real-World Post-Marketing Safety Data for Xarelto Presented

The post-marketing safety profile of Xarelto (rivaroxaban; Janssen) was consistent with the findings seen in the Phase 3 study, ROCKET AF, that supported the approval for Xarelto in the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF).
News

CHEST: New VTE Treatment Guidelines Released

The American College of Chest Physicians has released the latest evidence-based guideline with updated recommendations for appropriate treatment of patients with venous thromboembolism (VTE).
Drugs in the Pipeline

Reversal Agent for Factor Xa Inhibitors Under FDA Review

Portola Pharmaceuticals announced the submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for its investigational agent andexanet alfa, as a universal reversal agent for patients anticoagulated with an oral or injectable Factor Xa inhibitor who experience a serious uncontrolled bleeding event or who require urgent or emergency surgery. There is currently no…
Drug Monograph Updates

December 2015 Recap of Drug Updates

The summary below gives an overview of some of the important additions and changes MPR has made to its drug database through the end of December. The chart below provides highlights of the 118 key monograph updates made this month (not an inclusive list).